

FINANCIAL TEAR SHEET

Corporate Profile

KindredBio is focused on bringing breakthrough human products and innovative new technologies to veterinary medicine to address unmet clinical needs and provide benefits to animal companions.

The Approach

We identify drugs, biologics, and targets that have been validated in humans and develop animal versions to treat and cure pets. We seek to leverage the investments that have been made in human pharmaceutical R&D to develop therapies for pets with lower risk, lower cost, and shorter time-to-market, compared to human drug development.

The Opportunity

We believe KindredBio can deliver superior returns to investors because while the market sizes for pet drugs are about 10-fold smaller compared to human market sizes, the cost of development is 100-fold less.

World Class Team

KindredBio is one of the first pet biotechs in the world, and we have a world-class team, including the former Director of FDA's Center for Veterinary Medicine and the former Head of Biotherapeutics Clinical Research at Genentech. Because of the team, and because we do not outsource our clinical studies, we can move at a very rapid pace. We anticipate 2 launches in less than 2 years.

In addition, in the technically demanding area of biologics, KindredBio also has one of the most experienced teams in the pharmaceutical industry, with experts drawn from companies like Genentech and Amgen. We also have access to some of the most cutting-edge antibody technologies.

Contact Us

To contact investor relations, or to request an investor packet, please call 650.701.7904 or email IR@kindredbio.com.

Stock Information

KIN (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$12.66
Change (%)	▲ 0.36 (2.93%)
Volume	80,908
52 Week Low	\$6.95
Market Cap	\$417,131,966
Rolling EPS	-1.49
PE Ratio	0
Shares Outstanding	33,913,168

Data as of 11/15/18 4:00 p.m. ET



Recent Press Releases & Upcoming Events

November 7, 2018

There are currently no events scheduled.

[Kindred Biosciences Announces Third Quarter 2018](#)

[Financial Results](#)

October 30, 2018

[Kindred Biosciences Announces Positive Results from Pilot Effectiveness Study of its Fully Caninized IL-31 Antibody for the Treatment of Atopic Dermatitis in Dogs and Issuance of U.S. Patent](#)

October 24, 2018

[Kindred Biosciences to Announce Third Quarter 2018](#)

[Financial Results](#)

SEC Filings

Filing Date	Form
11/07/18	10-Q
11/07/18	8-K
11/02/18	4
10/31/18	4

Corporate Governance